Neutronic performance characteristics of different LEU fuels in a proposed NIST research reactor.

As a potential replacement for the National Bureau Standards Reactor (NBSR) at the U.S. National Institute of Standards and Technology (NIST), a conceptual design of a new reactor with a horizontally-split core has recently been studied using low-enriched uranium (LEU) silicide dispersion (USi/Al) fuel.

A critical examination of the results from the Harvard-MIT NCT program phase I clinical trial of neutron capture therapy for intracranial disease.

A phase I trial was designed to evaluate normal tissue tolerance to neutron capture therapy (NCT); tumor response was also followed as a secondary endpoint. Between July 1996 and May 1999, 24 subjects were entered into a phase I trial evaluating cranial NCT in subjects with primary or metastatic brain tumors. Two subjects were excluded due to a decline in their performance status and 22 subjects were irradiated at the MIT Nuclear Reactor Laboratory.